Eli Lilly will acquire the WUSTL-linked neurological disease therapy developer in a $135m deal that could top $1.2bn with milestone payments.

Eli Lilly has agreed to buy Disarm Therapeutics, a US-based neurological disease drug developer based on Washinton University in St Louis (WUSTL) research, for an upfront fee of $135m. Disarm is working on treatments for neurological disorders such as multiple sclerosis or amyotrophic lateral sclerosis (ALS) that are intended to work by inhibiting the SARM1…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.